Susquehanna International Group, LLP Clene Inc. Transaction History

Susquehanna International Group, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	SELL	$0.31 - $0.44 $387 - $549	-1,249 Reduced 3.0%	40,423 $14,000
Q1 2024 May 07, 2024	SELL	$0.28 - $0.53 $639 - $1,211	-2,285 Reduced 5.2%	41,672 $17,000
Q4 2023 Feb 14, 2024	BUY	$0.26 - $0.55 $3,023 - $6,394	11,627 Added 35.96%	43,957 $13,000
Q3 2023 Nov 14, 2023	SELL	$0.46 - $0.87 $3,742 - $7,078	-8,136 Reduced 20.11%	32,330 $16,000
Q2 2023 Aug 11, 2023	BUY	$0.78 - $1.22 $31,563 - $49,368	40,466 New	40,466 $35,000
Q4 2022 Feb 14, 2023	BUY	$0.92 - $40.2 $11,960 - $522,600	13,000 New	13,000 $13,000
Q4 2021 Feb 14, 2022	BUY	$3.95 - $7.53 $13,801 - $26,309	3,494 Added 19.12%	21,771 $90,000
Q3 2021 Nov 15, 2021	BUY	$6.83 - $13.58 $124,831 - $248,201	18,277 New	18,277 $125,000

230K

25K

Ticker CLNN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,502,000
Market Cap $273M
Description
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral scleros...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.